<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang H</submitter><funding>NCI NIH HHS</funding><funding>NIH</funding><funding>NIGMS NIH HHS</funding><pagination>e003339</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8705233</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>9(12)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Gamma delta (γδ) T cells are attractive effector cells for cancer immunotherapy. Vδ2 T cells expanded by zoledronic acid (ZOL) are the most commonly used γδ T cells for adoptive cell therapy. However, adoptive transfer of the expanded Vδ2 T cells has limited clinical efficacy.&lt;h4>Methods&lt;/h4>We developed a costimulation method for expansion of Vδ2 T cells in PBMCs by activating γδ T-cell receptor (γδTCR) and Toll-like receptor (TLR) 7/8 using isopentenyl pyrophosphate (IPP) and resiquimod, respectively, and tested the functional markers and antitumoral effects in vitro two-dimensional two-dimensional and three-dimensional spheroid models and in vivo models. Single-cell sequencing dataset analysis and reverse-phase protein array were employed for mechanistic studies.&lt;h4>R</pubmed_abstract><journal>Journal for immunotherapy of cancer</journal><pubmed_title>Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function.</pubmed_title><pmcid>PMC8705233</pmcid><funding_grant_id>CA114046</funding_grant_id><funding_grant_id>P50 CA261608</funding_grant_id><funding_grant_id>Tara Miller Melanoma Foundation</funding_grant_id><funding_grant_id>P30 CA016672</funding_grant_id><funding_grant_id>P30 CA010815</funding_grant_id><funding_grant_id>P01 CA114046</funding_grant_id><funding_grant_id>R35 GM141832</funding_grant_id><funding_grant_id>P50 CA174523</funding_grant_id><funding_grant_id>CA170340</funding_grant_id><pubmed_authors>Zhang G</pubmed_authors><pubmed_authors>Mitchell TC</pubmed_authors><pubmed_authors>Fan Y</pubmed_authors><pubmed_authors>Herlyn M</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Somasundaram R</pubmed_authors><pubmed_authors>Connelly T</pubmed_authors><pubmed_authors>Guo W</pubmed_authors><pubmed_authors>Dong L</pubmed_authors><pubmed_authors>Wang H</pubmed_authors><pubmed_authors>Chen H</pubmed_authors><pubmed_authors>Liu S</pubmed_authors><pubmed_authors>Huang L</pubmed_authors><pubmed_authors>Li L</pubmed_authors><pubmed_authors>Scholler J</pubmed_authors><pubmed_authors>Choi R</pubmed_authors><pubmed_authors>June CH</pubmed_authors><pubmed_authors>Lu H</pubmed_authors><pubmed_authors>Ou L</pubmed_authors><pubmed_authors>Yeye G</pubmed_authors><pubmed_authors>Tian S</pubmed_authors><pubmed_authors>Huang A</pubmed_authors><pubmed_authors>Xu X</pubmed_authors><pubmed_authors>Mills GB</pubmed_authors></additional><is_claimable>false</is_claimable><name>Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function.</name><description>&lt;h4>Background&lt;/h4>Gamma delta (γδ) T cells are attractive effector cells for cancer immunotherapy. Vδ2 T cells expanded by zoledronic acid (ZOL) are the most commonly used γδ T cells for adoptive cell therapy. However, adoptive transfer of the expanded Vδ2 T cells has limited clinical efficacy.&lt;h4>Methods&lt;/h4>We developed a costimulation method for expansion of Vδ2 T cells in PBMCs by activating γδ T-cell receptor (γδTCR) and Toll-like receptor (TLR) 7/8 using isopentenyl pyrophosphate (IPP) and resiquimod, respectively, and tested the functional markers and antitumoral effects in vitro two-dimensional two-dimensional and three-dimensional spheroid models and in vivo models. Single-cell sequencing dataset analysis and reverse-phase protein array were employed for mechanistic studies.&lt;h4>R</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Dec</publication><modification>2026-06-17T06:26:07.206Z</modification><creation>2022-02-11T15:11:43.237Z</creation></dates><accession>S-EPMC8705233</accession><cross_references><pubmed>34937742</pubmed><doi>10.1136/jitc-2021-003339</doi></cross_references></HashMap>